11 Jul 2017
N+1 Singer - Abzena - Licensing agreement demonstrates leading nature of ThioBridge™
The licensing agreement with OBI Pharma demonstrates the value and market-leading nature of Abzena’s ThioBridge™ technology. Abzena is eligible for up to £128m of milestone payments in addition to a royalty on potential sales. A master services agreement for process development and GMP manufacturing has also been established, validating the group’s rationale for investing in the expansion of its bio-manufacturing capability following the successful capital raise in April. We reiterate our positi ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Abzena - Licensing agreement demonstrates leading nature of ThioBridge™
Abzena (ABZA:LON) | 0 0 (-0.9%) | Mkt Cap: 54.0m
- Published:
11 Jul 2017 -
Author:
Dr Jens Lindqvist -
Pages:
3
The licensing agreement with OBI Pharma demonstrates the value and market-leading nature of Abzena’s ThioBridge™ technology. Abzena is eligible for up to £128m of milestone payments in addition to a royalty on potential sales. A master services agreement for process development and GMP manufacturing has also been established, validating the group’s rationale for investing in the expansion of its bio-manufacturing capability following the successful capital raise in April. We reiterate our positi ....